글로벌 항혈전제 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모                              

과응고성, 불규칙한 혈류, 혈관 내피 세포 손상은 혈전증의 세 가지 주요 원인입니다. 유전적 질환, 무활동, 흡연, 혈관 질환, 임신 및 비만은 모두 기여 요인입니다. 다양한 형태의 혈전증 치료법이 현재 시중에 나와 있습니다. 일반적으로 혈액 응고제로 알려진 항응고제는 혈전증의 1차 치료법입니다. 이러한 약물은 주로 효소 작용을 통해 혈전을 분해하거나 용해하는 데 사용됩니다. 시중에 나와 있는 주요 혈전증 약물에는 Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin, Rivaroxaban 및 Warfarin이 있습니다. 헤파린 및 와파린 약물은 예측 기간 동안 모든 약물 중에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

Data Bridge Market Research는 항혈전제 시장이 2021년에 41,697.49백만 달러 규모였으며 2029년까지 76,722.98백만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 7.92%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

항혈전제는 혈전이나 혈전 발생을 예방하는 데 도움이 됩니다. 항혈전제와 항응고제는 신체의 혈전 형성 능력을 낮춥니다. 이러한 약물은 간에서 비타민 K를 생성하는 것을 차단하여 작용합니다. 항혈전제에는 항혈소판제 , 항응고제 및 혈전 용해제가 있으며, 이는 서로 다른 응고 경로에 작용합니다. 항혈전제는 각각 동맥 및 정맥 혈전증을 치료하는 데 사용할 수 있습니다.

항혈전제 시장 동향

운전자

• 만성 질환의 유병률 증가

암 , 고혈압, 심장 관련 질환 과 같은 만성 질환의 유병률 증가는 산업 성장을 촉진할 것입니다. 심혈관 질환(CVD)은 전 세계적으로 가장 큰 사망 원인으로, 매년 약 1,790만 명이 사망합니다. 심장마비와 뇌졸중은 CVD 사망의 5분의 4 이상을 차지하며, 이 중 3분의 1은 70세 이전에 발생합니다.

• 노령 인구 증가

항혈전제 시장은 대부분 국가의 인구 고령화로 인해 성장했습니다. 인구 참조국 통계에 따른 추산에 따르면, 전 세계 65세 이상 인구는 2014년에서 2017년 사이에 4억 5천만 명에서 6억 1천만 명으로 33% 증가했습니다. 예측 기간 동안 이러한 추세는 지속될 것으로 예상됩니다. 일본에서는 노인 비율이 2012년 24%에서 2050년 40%로 증가할 것으로 예상됩니다. 인구 고령화로 인해 사망의 주요 원인인 심혈관 질환을 앓고 있는 사람의 수가 증가했습니다.

Furthermore, surging number of government initiatives to spread awareness will result in the expansion of antithrombotic drugs market. Along with this, sedentary lifestyle of people and favourable reimbursement policies will enhance the growth rate of the market. Another significant factor influencing the growth rate of antithrombotic drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

Opportunities

• Growing demand for NOACS

Increased demand for NOACS, as well as government healthcare policies and programmes, are key drivers of growth in the worldwide antithrombotic medicines market. The market is growing due to the rising acceptance of NOACs. To prevent and cure thrombosis, NOACs target either thrombin or factor Xa. They demonstrate fast activity and do not necessitate constant supervision. The administrations of the various regions are taking steps to improve the health of the country. This will provide new market opportunities.

Moreover, the market's growth is fueled by an increase in the number of research and development activities for the new drug development and new product launches. These factors will provide beneficial opportunities for the antithrombotic drugs market growth.

Restraints/Challenges

• Side effects linked with antithrombotic drugs

As side effects are primary consideration for thrombosis patients, doctors frequently try to offer alternative therapies to their patients, and this factor is anticipated to hinder the market's growth throughout the projection period. Higher bruising, red or pink coloured urine, more bleeding than normal in female menstrual periods, pain, increased risk of pregnancy difficulties, and a change in temperature are the most common antithrombotic medication adverse effects. If a woman is pregnant while using warfarin, for instance, the medicine can cause foetal mortality.

On the other hand, high cost associated with the drug development and distribution will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the antithrombotic drugs market. Additionally, lack of awareness among people and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This antithrombotic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antithrombotic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Antithrombotic drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Antithrombotic Drugs Market

Due to the rapid speed of research, COVID-19 infection is predicted to have a significant influence on the antithrombotic drugs market. As per a study published in the American Journal of Cardiovascular Drugs in 2020, more than ten clinical trials are currently underway to assess the potential of antithrombotic drugs in COVID-19 patients, and research on parenteral administration strategies for these drugs is being conducted for use in critically ill COVID-19 patients. Furthermore, patients with COVID-19, both confirmed and suspected, should have access to follow-up care with low-dose antithrombotic drugs, according to a World Health Organization Update published in January 2021. As a result, antithrombotic drugs demand surged during COVID-19.

Recent Development

• In December 2020, Natco Pharma had announced the launch of an antithrombotic drugs medication named Rivaroxaban (RPIGAT). Rivaroxaban is an antithrombotic drugs drug that treats and prevents blood clots. In India, Bayer markets the drug as Xarelto.

Global Antithrombotic Drugs Market Scope

The antithrombotic drugs market is segmented on the basis of type, drug class, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Apixaban
• Debigatran
• Edoxaban
• Fondaparinux
• Heparin
• Rivaroxaban

Indication

• Atrial Fibrillation
• Stroke
• Deep vein thrombosis (DVT)
• Pulmonary Embolism (PE)
• Others

Drug Class

• Thrombolytic Drugs
• Anti-Platelet Drugs
• Anticoagulants
• Others

Route of Administration

• Oral
• Injectable
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Antithrombotic Drugs Market Regional Analysis/Insights

The antithrombotic drugs market is analysed and market size insights and trends are provided by country, type, drug class, indication, route of administration, end-users and distribution channel as referenced above.

The countries covered in the antithrombotic drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the antithrombotic drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing cardiac and cancer diseases and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.

Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to surging number of geriatric population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Antithrombotic Drugs Market Share Analysis

항혈전제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 항혈전제 시장과 관련된 회사의 초점에만 관련이 있습니다.

항혈전제 시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 머크앤코(미국)
• 알러간(아일랜드)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 히크마 제약(영국)
• Fresenius Kabi AG(독일)
• 에자이 주식회사(일본)
• 브리스톨-마이어스 스퀴브 회사(미국)
• Bayer AG(독일)
• 다이이치 산쿄 주식회사(일본)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• Dr. Reddy's Laboratories Ltd. (인도)
• Aspen Holdings(남아프리카 공화국)

SKU-53274